| Catalog Number |
04V51-21 |
| Medical Device Problem Code |
High Test Results (2457)
|
| Health Effect - Clinical Code |
No Clinical Signs, Symptoms or Conditions (4582)
|
| Date of Event |
01/01/2017
|
|
Type of Reportable Event
|
Malfunction
|
|
Additional Manufacturer Narrative
|
|
The complaint investigation for falsely elevated alinity c total bilirubin results included a review of data and information provided by the customer, search for similar complaints, ticket trending review, labeling review, and device history record review.Data and information provided by the customer were reviewed.Return testing was not completed as returns were not available.Review of tracking and trending for the alinity c total bilirubin assay did not identify an increase in complaint activity related to the complaint issue, however, a search for similar complaints could not be performed as the complaint lot number is unknown.The device history record did not identify any nonconformances related to the likely cause list number and complaint issue.Labeling was reviewed and sufficiently addresses the customer's issue.Based on the investigation, no systemic issue or deficiency with the alinity c total bilirubin assay for unknown lot was identified.
|
| |
|
Event or Problem Description
|
|
The customer observed falsely elevated alinity c total bilirubin results generated on the alinity c processing module for one patient when compared to other reference labs using a different method.The customer observed the results from the alinity are high while the results from the reference labs (b)(6) are in the normal range of 0.2-1.2 mg/dl.The customer states the doctor declined to provide results from the reference labs.The customer reviewed the patient results from their facility with results going back to 2017 ranging from 1.3-2.6 mg/dl.Customer states they have no issues with cap failures, calibrations, or quality control issues.The following data was provided: patient total bilirubin results from abbott instrumentation at the (b)(6) (unknown which are architect or alinity): (b)(6) 2023 sid (b)(6) result = 2.3 mg/dl (b)(6) 2023 sid (b)(6) result = 1.8 mg/dl (b)(6) 2023 sid (b)(6) result = 1.9 mg/dl (b)(6) 2022 sid (b)(6) result = 1.7 mg/dl (b)(6) 2022 sid(b)(6) result = 1.7 mg/dl no impact to patient management was reported.
|
| |
|
Event or Problem Description
|
|
The customer observed falsely elevated alinity c total bilirubin results generated on the alinity c processing module for one patient when compared to other reference labs using a different method.The customer observed the results from the alinity are high while the results from the reference labs (b)(6) and mayo clinic roche method are in the normal range of 0.2-1.2 mg/dl.The customer states the doctor declined to provide results from the reference labs.The customer reviewed the patient results from their facility with results going back to 2017 ranging from 1.3-2.6 mg/dl.Customer states they have no issues with cap failures, calibrations, or quality control issues.The following data was provided: patient total bilirubin results from abbott instrumentation at the (b)(6) hospital (unknown which are architect or alinity): (b)(6) 2023 sid 237-01158 result = 2.3 mg/dl.(b)(6) 2023 sid 237-00101 result = 1.8 mg/dl.(b)(6) 2023 sid 236-01557 result = 1.9 mg/dl.(b)(6) 2022 sid 202-00572 result = 1.7 mg/dl.(b)(6) 2022 sid 201-02595 result = 1.7 mg/dl.No impact to patient management was reported.
|
| |
|
Additional Manufacturer Narrative
|
|
Section a1 patient identifier complete information: (b)(6).An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.All available patient information was included.Additional patient details are not available.
|
| |
|
Search Alerts/Recalls
|